Jenike M A, Albert M S, Heller H, Gunther J, Goff D
Division on Aging, Harvard Medical School, Boston, MA.
J Clin Psychiatry. 1990 Jan;51(1):3-7.
Twelve patients aged 53 to 89 years with presenile or senile dementia of the Alzheimer's type participated in a treatment trial of oral physostigmine. Patients first received the drug during an open dose-finding phase. In a double-blind crossover design phase, the patients' memory performance during treatment with an optimal memory-enhancing dose was compared with memory performance during placebo treatment. Response to medication was assessed by the Delayed Recognition Span Test, the Selective Reminding Test, and the Alzheimer's Disease Assessment Scale. Intergroup differences in response to physostigmine were nonsignificant. Age at onset of the disease did not differentiate partial responders from nonresponders.
12名年龄在53至89岁之间、患有早老性或老年性阿尔茨海默型痴呆症的患者参与了口服毒扁豆碱的治疗试验。患者首先在开放剂量探索阶段接受该药物。在双盲交叉设计阶段，将患者在使用最佳记忆增强剂量治疗期间的记忆表现与安慰剂治疗期间的记忆表现进行比较。通过延迟识别跨度测试、选择性提醒测试和阿尔茨海默病评估量表评估对药物的反应。毒扁豆碱反应的组间差异不显著。疾病发病年龄并不能区分部分反应者和无反应者。
